Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Ramucirumab Improves PFS in Phase III Urothelial Carcinoma Trial

May 31st 2017

Adding ramucirumab (Cyramza) to docetaxel led to a statistically significant improvement in progression-free survival (PFS) versus docetaxel alone in previously treated patients with locally advanced or unresectable or metastatic urothelial carcinoma.

Dr. Kaouk on a Study of Robotic Surgery in Kidney Cancer

May 26th 2017

Jihad Kaouk, MD, urologist, Cleveland Clinic, discusses how robot-assisted partial nephrectomy for selected renal mass using off-clamp approach offered renal functional advantage over on-clamp approach.

Dr. Daneshmand on Blue Light Cystoscopy for Bladder Cancer

May 26th 2017

Siamak Daneshmand, MD, associate professor of Urology, Director of Clinical Research, Keck School of Medicine of USC, discusses blue light cystoscopy compared with white light cystoscopy for patients with bladder cancer.

Post-TURBT Gemcitabine Reduces Recurrence in Bladder Cancer

May 26th 2017

Edward Messing, MD, discusses how treatment with gemcitabine following transurethral resection of bladder tumors reduced the risk of recurrence by 34% in patients with non-muscle invasive disease.

Dr. Badani on the Benefits of Robotic Surgery for Kidney Cancer

May 25th 2017

Ketan K. Badani, MD, professor of Urology at Mount Sinai Hospital, discusses the benefits of performing a partial robotic nephrectomy for patients with kidney cancer.

Dr. Rosenberg on Non-Metastatic Muscle Invasive Bladder Cancer Guidelines

May 25th 2017

Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the new treatment guidelines for patients with non-metastatic muscle invasive bladder cancer.

ODAC Recommends Approval of Epoetin Alfa Biosimilar

May 25th 2017

The FDA’s Oncologic Drugs Committee voted 14-1 to recommend approving a biologics license application for epoetin hospira (Retacrit), an epoetin alfa (Epogen/Procrit) biosimilar manufactured by Hospira.

Dr. Lallas on Immunotherapy Combinations in Genitourinary Malignancies

May 22nd 2017

Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses combinations of immunotherapy for genitourinary malignancies.

Lead Researcher Discusses FDA Approval of Pembrolizumab for Urothelial Carcinoma

May 22nd 2017

Arjun V. Balar, MD, discusses the impact of the approval of pembrolizumab and other immunotherapy agents in urothelial carcinoma, as well as the next steps with these treatments.

Precision Medicine Circa 2017

May 20th 2017

Raoul S. Concepcion, MD, discusses the new era of molecular testing and screening and how it has impacted the field of prostate cancer thus far.

SouthWest Urology Uses Quality-Focused Integrated Care Mode

May 19th 2017

Michael Barkoukis, MD, and Tim Sidor, MD, started SouthWest Urology of Cleveland, OH, in 1982 from scratch with $100,000 in borrowed capital, a box of pens, and a copy machine.

Dr. Petrylak on FDA Approval of Pembrolizumab in Bladder Cancer

May 18th 2017

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of patients with bladder cancer.

FDA Approves Pembrolizumab for Urothelial Carcinoma

May 18th 2017

The FDA has granted pembrolizumab approvals in the frontline and second-line settings for urothelial carcinoma.

Dr. Black on Combinations with Durvalumab in Bladder Cancer

May 17th 2017

Peter Black, MD, senior research scientist, Vancouver Prostate Center, associate professor, Department of Urologic Sciences, University of British Columbia, discusses combination trials with durvalumab (Imfinzi) for patients with bladder cancer.

Dr. Gupta on VEGF Inhibitors Combined with Immunotherapy in Kidney Cancer

May 17th 2017

Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses combining VEGF inhibitors with immunotherapy for patients with kidney cancer.

Dr. Campbell on the Guidelines for the Management of Kidney Cancer

May 16th 2017

Steven Campbell, MD, PhD, urologist, Cleveland Clinic, discusses the recent guidelines for the management of patients with kidney cancer.

Dr. Bratslavsky on the Evaluation and Management of Kidney Cancer

May 16th 2017

Gennedy Bratslavsky, MD, deputy director of Upstate Cancer Center, director of the Robotic Program for all Upstate Campuses, and director of the VHL Clinical Cancer Center, discusses the evaluation and management of kidney cancer.

Dr. Raman on Hematuria in Urothelial Cancer

May 16th 2017

Jay D. Raman, MD, professor of Surgery and chief of the Division of Urology at Penn State Milton S. Hershey Medical Center, discusses hematuria in patients with urothelial carcinoma.

Burnout in Urologists Lower Than Prior Reports, But Remains Serious Issue

May 15th 2017

As part of the 2016 American Urological Association Census, investigators randomly assigned Maslach Burnout Inventory questions to determine how many urologists met the criteria for burnout.

Complete Surgical Metastasectomy Remains Critical Option in RCC

May 12th 2017

Bradley C. Leibovich, MD, discusses the benefits of surgery and the need for more effective drug treatments for patients with metastatic renal cell carcinoma.